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Current models of progression in neurodegenerative diseases use neuroimaging measures that are averaged across
pre-deﬁned regions of interest (ROIs). Such models are unable to recover ﬁne details of atrophy patterns; they
tend to impose an assumption of strong spatial correlation within each ROI and no correlation among ROIs. Such
assumptions may be violated by the inﬂuence of underlying brain network connectivity on pathology propagation
– a strong hypothesis e.g. in Alzheimer's Disease. Here we present DIVE: Data-driven Inference of Vertexwise
Evolution. DIVE is an image-based disease progression model with single-vertex resolution, designed to recon-
struct long-term patterns of brain pathology from short-term longitudinal data sets. DIVE clusters vertex-wise (i.e.
point-wise) biomarker measurements on the cortical surface that have similar temporal dynamics across a patient
population, and concurrently estimates an average trajectory of vertex measurements in each cluster. DIVE
uniquely outputs a parcellation of the cortex into areas with common progression patterns, leading to a new
signature for individual diseases. DIVE further estimates the disease stage and progression speed for every visit of
every subject, potentially enhancing stratiﬁcation for clinical trials or management. On simulated data, DIVE can
recover ground truth clusters and their underlying trajectory, provided the average trajectories are sufﬁciently
different between clusters. We demonstrate DIVE on data from two cohorts: the Alzheimer's Disease Neuro-
imaging Initiative (ADNI) and the Dementia Research Centre (DRC), UK. The DRC cohort contains patients with
Posterior Cortical Atrophy (PCA) as well as typical Alzheimer's disease (tAD). DIVE ﬁnds similar spatial patterns of
atrophy for tAD subjects in the two independent datasets (ADNI and DRC), and further reveals distinct patterns of
pathology in different diseases (tAD vs PCA) and for distinct types of biomarker data – cortical thickness from
Magnetic Resonance Imaging (MRI) vs amyloid load from Positron Emission Tomography (PET). We demonstrate
that DIVE stages have potential clinical relevance, despite being based only on imaging data, by showing that the
stages correlate with cognitive test scores. Finally, DIVE can be used to estimate a ﬁne-grained spatial distribution
of pathology in the brain using any kind of voxelwise or vertexwise measures including Jacobian compression
maps, fractional anisotropy (FA) maps from diffusion tensor imaging (DTI) or other PET measures.1. Introduction
Many biomarkers exist that can be used to track the severity of
neurodegenerative diseases such as Alzheimer's disease (AD). Clinical
function can be measured using cognitive assessments performed by an
expert clinician and brain atrophy can be measured using Magneticing, Torrington Place, London, W
(R.V. Marinescu).
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evier Inc. This is an open accessResonance Imaging (MRI). Other measures include molecular markers
such as aggregation of misfolded amyloid-beta or tau measured using
Positron Emission Tomography (PET), and measures of white-matter
degradation such as fractional anisotropy (FA) from Diffusion Tensor
Imaging (DTI). The evolution of these biomarkers across the disease time-
course creates a unique signature of the disease that can be used to stageC1E 7JE, United Kingdom.
ebruary 2019
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
R.V. Marinescu et al. NeuroImage 192 (2019) 166–177patients, which may potentially help stratiﬁcation in clinical trials
(Holland et al., 2012).
A hypothetical model of disease progression has been proposed by
(Jack Jr et al., 2010), describing the order of abnormality of key bio-
markers along the progression of AD. The model suggests that
amyloid-beta and tau biomarkers become abnormal long before symp-
toms appear, followed by brain atrophy measures and cognitive decline.
Motivated by this hypothetical model, several data-driven disease pro-
gression models have been proposed in recent years, which aggregate
information from multiple biomarkers into a single time frame repre-
senting disease progression. One such model is the Event-Based Model
(EBM) (Fonteijn et al., 2012; Young et al., 2014), which models the
progression of disease as a sequence of discrete events, representing
underlying biomarkers switching from a normal to abnormal state. Other
types of disease progression models (Donohue et al., 2014; Jedynak et al.,
2012; Li et al., 2017; Lorenzi et al., 2017; Schiratti et al., 2015) have been
developed, that build continuous trajectories by “stitching” together
short-term follow-up data from individual subjects. In contrast to the
discrete disease stages that are estimated by the EBM, these models also
compute a continuous measure of disease stage for every individual by
estimating individual time shifts and progression speeds.
Current image-based disease progression models estimate the evolu-
tion of the disease using a small set of biomarkers corresponding to pre-
deﬁned regions-of-interest (ROI). This ROI parcellation is usually coarse,
doesn't allow one to ﬁnd spatially dispersed patterns of atrophy. While
spatiotemporal longitudinal models have already been demonstrated
(Derado et al., 2010; Hyun et al., 2016; Lorenzi et al., 2015), these
models regress against pre-deﬁned sets of covariates such as age, time
since baseline or clinical markers. This is problematic because, age-based
alignment of subjects assumes all subjects have the same age of disease
onset, while for time since baseline, its relationship with disease onset is
unknown. Similarly, clinical markers are noisy, biased, suffer from
ﬂoor/ceiling and training effects, are not sensitive in pre-symptomatic
phases, and have low test-retest reliability (Johnson et al., 2012).
Recently, some spatiotemporal models that estimate subject-speciﬁc time
shifts have been developed (Bilgel et al., 2016; Koval et al., 2017).
However, these models generally cannot recover dispersed and discon-
nected pathological patterns, because they assume correlation of voxels
based on spatial distance, either through a distance function or distance
from control points. However, spatially dispersed pathological patterns
have been observed in AD and related dementias and are hypothesized to
appear due to interactions of pathology and brain networks (Seeley et al.,
2009). Discovering such ﬁne-grained patterns could provide new insight
into underlying mechanisms of pathology propagation along these brain
networks (Seeley et al., 2009; Zhou et al., 2012). However, a spatio-
temporal disease progression model that allows recovery of dispersed
atrophy patterns present in AD, is not currently available.
In this work, we present DIVE: Data-driven Inference of Vertexwise
Evolution. DIVE is a novel disease progression model with single vertex
resolution that makes only weak assumptions on spatial correlation. In
contrast to approaches which model temporal trajectories for a small set
of biomarker measures based on a priori deﬁned ROIs, DIVE models
temporal trajectories for each vertex on the cortical surface. DIVE com-
bines unsupervised learning and disease progression modelling to iden-
tify clusters of vertices on the cortical surface that show a similar
trajectory of brain pathology over a particular patient cohort. This
formulation enables us to estimate a ﬁne-grained spatial distribution of
pathology and also provides a novel parcellation of the brain based on
temporal change. In this exploratory study, we aim to demonstrate in
Alzheimer's disease DIVE's ability to identify new detail in pathology
patterns, as well as evaluate the potential beneﬁt of estimating ﬁne-
grained patterns of pathology for disease staging and prognosis. We
ﬁrst test DIVE on synthetic data and show that the model can recover
known biomarker trajectories and disease progression scores (DPS). We167then demonstrate the model on both MRI and PET data from two cohorts:
the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the De-
mentia Research Centre (DRC), UK, containing patients with Posterior
Cortical Atrophy. We use the model to reveal spatiotemporal patterns of
pathology to a much ﬁner resolution than previous models and demon-
strate the ability to assign subjects to stages that predict progression.
Finally, we validate DIVE in terms of how robust are the estimated pa-
thology patterns and how well the disease progression scores correlate
with cognitive tests. Source code for DIVE is available online: https://gith
ub.com/mrazvan22/dive.
2. Method
In this section we describe the mathematical formulation of DIVE
(section 2.1), then we show how to ﬁt the model using Expectation
Maximisation (section 2.2) and we describe further implementation de-
tails of the algorithm (section 2.3). Afterwards, we outline the synthetic
data-generation process (section 2.4) for testing the model in the pres-
ence of ground truth, as well as the pipeline for pre-processing the ADNI
and DRC datasets (section 2.5).2.1. The DIVE model
Fig. 1 illustrates the DIVE aims and implementation. As opposed to
previous models (Donohue et al., 2014; Jedynak et al., 2012) that used
extracted features as input, DIVE input measures are vertexwise or vox-
elwise biomarker measures in the brain (Fig. 1A), such as cortical
thickness or amyloid load. A vertex is a location on the cortical surface at
which a biomarker of pathology is quantiﬁable (e.g. cortical thickness).
For each vertex on the cortical surface (or voxel in the 3D brain volume),
we estimate a unique trajectory along the disease progression timeline
(Fig. 1B), while also estimating subject/visit-speciﬁc disease progression
scores (i.e. disease stages). We do that by grouping vertices with similar
biomarker trajectories into clusters (Fig. 1C), and we estimate a repre-
sentative trajectory for every cluster (Fig. 1D). Each trajectory is a
function of subject-/visit-speciﬁc disease progression scores (DPS)
(Fig. 1E). The DPS depends linearly on the time since baseline visit, but
with subject-speciﬁc slope and intercept.
2.1.1. Modelling subject-speciﬁc time shifts and progression speeds
The disease progression score sij for subject i at visit j is a latent
variable denoting the current disease stage of the subject at this visit. It is
deﬁned as a linear transformation of time since baseline measurement tij
(in years):
sij ¼ αitij þ βi (1)
where αi and βi represent the speed of progression and time shift (i.e.
disease onset) of subject i. The range of DPS is (-∞, þ∞), where large
positive values are indicative of advanced stages of pathology. For
interpretability, we later standardise the values so that the DPS of con-
trols follow a N(0,1) distribution, so any DPS above 1 can be considered
abnormal.
2.1.2. Modelling biomarker trajectory for a single vertex
DIVEassumes that the biomarkermeasure at each vertex on the cortical
surface follows a sigmoidal trajectory f(.; θ) over the disease progression
score s and with parameters θ. We choose a parametric sigmoid function
because it is a parsimonious parametric model that offers better ﬁt
compared to linear models, is monotonic, and can account for ﬂoor and
ceiling effects (Caroli and Frisoni, 2010; Sabuncu et al., 2011). We also
assume that vertices are grouped into K clusters and we model a unique
trajectory for each cluster k 2 [1,…, K], whichwill be referred to as cluster
trajectories. The trajectory function f(s; θk) for cluster k for is deﬁned as:
Fig. 1. Diagram of the proposed DIVE model. DIVE assumes that biomarkers of pathology (e.g. cortical thinning) can be measured at many vertices (i.e. locations) on
the cortical surface (A), where each vertex has a distinct trajectory of change during disease progression (B). In (B), each individual has measurements for vertex 1 at
three visits. DIVE assigns to every cortical vertex one of a small set of temporal trajectories describing the change in some image-based measurement (e.g. cortical
thickness, amyloid PET, DTI fractional anisotropy measures) from beginning to end of the disease progression. The estimation process simultaneously estimates the set
of clusters, the trajectory deﬁning each cluster, and the disease progression scores, representing the position of each subject along the latent disease space. The process
iterates assignment of each vertex to clusters (red, green and blue in this diagram) (C), estimation of the trajectory in each cluster (D) and estimation of the disease
progression score for each subject (E), all within an expectation-maximisation framework, until convergence. In particular, (E) shows how the disease progression
score, which is initially set to the individual's age, converges to the disease stage of the subject.
R.V. Marinescu et al. NeuroImage 192 (2019) 166–177f ðs ; θkÞ ¼ ak1þ expð  bkðs ckÞÞ þ dk (2)where s is the disease progression score from Eq. (1) and θk¼ [ak, bk, ck,
dk] are parameters controlling the shape of the trajectory – dk and dkþ ak
represent the lower and upper limits of the sigmoidal function, ck rep-
resents the inﬂection point and akbk/4 represents the slope at the in-
ﬂection point.
For parsimony, we model the all vertices within a cluster with the
same trajectory. For a given subject i at visit j, the value Vlij of its
biomarker measurement at vertex l is a random variable that has an
associated discrete latent variable Zl 2 [1, …, K] denoting the cluster it
was generated from. The value of Vlij given that it was generated from




αi; βi; θZl ; σZl ;Zl ¼ NVijl f αitij þ βi; θZl; σZl (3)
where N(Vlij jf(αi tij þ βi; θZl), σZl) represents the probability density
function (pdf) of the normal distribution that models the measurement
noise along the sigmoidal trajectory of cluster Zl, having variance σZl.
Next, we assume the measurements from different subjects are in-
dependent, while the measurements from the same subject i at different
visits j are linked using the disease progression score from Eq. (1).
Moreover, we also assume a uniform prior on cluster membership Zl. This
gives the following model:






f αitij þ βi; θZl; σZl (4)
where I¼ [(i, j)] represents the set of all the subjects i and their corre-
sponding visits j. Furthermore, Vl¼ [Vlij j (i,j) 2 I] is the 1D array of all the
values for vertex l across every visit of every subject. Vectors α¼ [α1, …,
αS] and β¼ [β1, …, βS], where S is the number of subjects, denote the
stacked parameters for the subject shifts. If a subject i has multiple visits,
these visits share the same parameters αi and βi. Vectors θ¼ [θ1, …, θK]168and σ ¼ [σ1, …, σK], with K being the number of clusters, represent the
stacked parameters for the sigmoidal trajectories and measurement noise
speciﬁc to each cluster.
2.1.3. Modelling biomarker trajectories for all vertices
So far we have a model for only one vertex on the brain surface. We
therefore extend the formulation to all the vertices by assuming all these
vertex measurements are spatially independent, giving the complete data
likelihood:








f αitij þ βi; θZl; σZl (5)
where V¼ [V1,…, Vl], Z¼ [Z1,…, Zl], L being the total number of vertices
on the cortical surface. The formulation assumes spatial independence
between measurements in different vertices, but in section 2.1.4 the
model is extended to capture spatial correlations. We get the ﬁnal model
log likelihood for incomplete data by marginalising over the latent var-
iables Z:











f αitij þ βi; θk; σk (6)
Throughout the article, we will use the shorthand zlk¼ p(Zl¼ k).
2.1.4. Modelling spatial correlation
The model so far assumes spatial independence between hidden Zl
variables, conditional on the parameters [α, β, θ, σ]. However, the
regional organisation of the cortex suggests we would expect spatial
correlation of the vertex measurements. More precisely, measures of
cortical thickness or other modalities are often similar in neighbouring
vertices on the cortical surface and likely belong to the same cluster.
The model is now extended to include mild spatial constraints on the
correlation of vertex measurements via a Markov Random Field (MRF),
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sponding cluster (Bishop, 2006). We hypothesise that incorporating
such constraints should reduce the effects of noise and produce a more
stable clustering with “ﬁlled holes”. However, this does not model
correlation between the actual vertex values, but only between the
latent variables Zl, i.e. the cluster membership of each vertex. The MRF
thus has the advantage of not requiring the use of huge covariance
matrices, which are otherwise needed if we want to model correlation
of vertex values directly. More precisely, the dimensionality of Z is L
(number of vertices, here around 160,000) x K (number of clusters)
instead of L x L for covariance matrices. Moreover, in contrast to pre-
vious methods that use correlation based on spatial distance (Bilgel
et al., 2016; Koval et al., 2017), we use neighbourhood correlations,
which allow us to estimate ﬁne-grained spatial patterns of pathology.
With the MRF, the full-data likelihood function of the model now
becomes:













where Ψ(Zl, Zl2) is a clique term representing the likelihood of a neigh-
bouring vertex l2 to have similar label with vertex l. The formula for the
clique term is:
Ψ ðZl ¼ k;Zl2 ¼ k2Þ ¼

expðgðλÞÞ if k ¼ k2
expðhðλÞÞ otherwise (8)
where λ is a parameter controlling how much to penalise neighbouring
vertices that belong to distinct clusters, and g and h are positive, mono-
tonic functions over the λ> 0 range. We choose g(λ)¼ λ and h(λ)¼ λ2,
which results in a concave objective function for λ, ensuring that it can
later be optimised (see M-step).
Therefore, the model parameters that need to be estimated are
M¼ [α, β, θ, σ, λ] where α and β are the subject speciﬁc shifting pa-
rameters, θ and σ are the cluster speciﬁc trajectory and noise param-
eters and λ controls the penalisation of vertices belonging to different
clusters.2.2. Fitting the model using generalised expectation-maximisation
We choose to ﬁt our model using Expectation-Maximisation (EM),
because it offers a fast convergence given the large number of parameters
that need to be estimated and the huge dimensionality of relevant
datasets (e.g. 1973 subjects x 163,842 vertices in ADNI). This is because
an approximate form of the incomplete-data log-likelihood is used that
can be evaluated (i.e. is computationally tractable). Moreover, highly-
coupled parameters are optimised jointly, while low-coupled parame-
ters are optimised independently. In the next two sections we outline the
E-step and M-step. While both of these steps have no closed-form solu-
tion, we will solve them using numerical optimisation, which only results
in an increase in the objective function at each iteration. However, the
EM algorithm is still guaranteed to converge, and this approach is called
Generalised EM (Bishop, 2006).
Algorithm 1 shows the model ﬁtting procedure using the EM algo-
rithm. The procedure ﬁrst initialises (line 1) some parameters required to
start the EM algorithm: the subject-speciﬁc parameters α and β and the
latent parameters zlk which represent the assignment of vertices to
clusters. In the M-step, the method updates the trajectories of each cluster
(lines 4–6), the subjects-speciﬁc parameters (line 9) and the clique pen-
alty term λ (line 17). In the E-step, the method computes zlk (line 18)
using previously deﬁned functions that compute zlk given a ﬁxed λ (line
14).
Algorithm 1. The optimisation procedure for ﬁtting DIVE using the
Expectation-Maximisation algorithm.1692.2.1. E-step
In the Expectation step, at iteration u we seek an estimate of p(Z jV,
M(u1)), given the current estimates of the parameters M(u1)¼ [ θk(u1),
σk
(u1), αi(u1), βi(u1), λi(u1)]. We perform this using Iterated Conditional
Modes (Bishop, 2006), which performs coordinate-wise gradient ascent.
This works by conditioning the clique terms Z on the values of Z from the











The factorised form allows for tractable computation and memory
storage of p(Z).
Let zlk(u)¼ p(Zl¼ k j Vl, M(u1),Z(u1)). After simpliﬁcations we reach





















λ2þ zðu1Þl2k expðλÞ  expλ2i
#
(10)
The full derivation is given in the Supplementary material. In order to
enable optimisation over λ, a ﬁnal modiﬁcation of this step is performed,
by considering zlk to be functions ζlk(λ) over λ. This results in the update
equation from Alg. 1, line 18 which is based on pre-deﬁned terms on lines
13–14.
2.2.2. M-step
In the Maximisation step we try to estimate the model parameters
M¼ (α, β, θ, σ, λ) that maximise EZjV,M(u1)[log p(V,ZjM)]. We cannot simul-
taneously optimise all 5 sets of parameters, so we optimise them inde-
pendently. To get the update rule for the trajectory parameters θk
corresponding to cluster k we need to maximise the expected log likeli-
hood with respect to θk. The key observation here is that if we assume
ﬁxed α, β and Z, then the trajectory parameters θk for every cluster k are
conditionally independent, i.e. θk ? θm j (Z, α, β, σ) 8 (k, m), k 6¼ m. This
allows us to maximise every θk independently using the following
equation:















f αitij þ βi; θzl; σzl
#
þ log pðθkÞ (11)
A similar observation of conditional independence can also be
observed for the latent variables Z. This allows us to decompose the joint
distribution over Z, and after expanding the noise model we reach the
optimisation problem from Alg. 1, line 4. See Supplementary material for
full derivation. This does not have a closed-form solution, so we use
numerical optimisation for ﬁnding θk that maximises the equation from
Alg. 1, line 4.
A similar equation, yet in closed form, is also obtained for σk (Alg. 1,
line 6). After estimating θ and σ for every cluster, we use the new values
to estimate the subject speciﬁc parameters α and β. For every subject i, we
maximise the expected log likelihood with respect to αi, βi independently,
and after simpliﬁcations we obtain the update rule from Alg. 1, line 9,
which is again solved using numerical optimisation. For the numerical
optimisation of θ we used the Nelder-Mead method for its robustness,
while for α and β we used the second-order Broyden–-
Fletcher–Goldfarb–Shanno (BFGS) algorithm due to fast convergence.
Finally, we achieved a signiﬁcant speed-up in the evaluation of objective
functions by computing a zlk-weighted average of vertex measurements
within each cluster (see Supplementary section 5). This resulted in a
convergence time of around 6 h for the larger datasets (ADNI).
For optimising λ, we again try to optimise in the M-step the expected








We simplify the above equation by expanding the likelihood model
and approximating the joint over Z with the product of the marginals zlk
over all vertices l. This results in the update equation from Alg. 1 line 17 –
see supplementary material for full derivation. In this ﬁnal equation we
also replaced zlk with a function ζlk(λ) over λ, which updates zlk based on
the current value of λ being evaluated. This is done to increase conver-
gence, as latent variables zlk are highly coupled with the value of λ being
evaluated.
2.3. Implementation details
2.3.1. Parameter initialisation and priors
Before starting the ﬁtting process, we need to initialise α, β and the
clustering probabilities zlk (Alg. 1, line 1). We set αi and βi to be 1 and
0 respectively for each subject, which sets the initial disease progression
score to the time since baseline of the subject at the clinical visit. In line
with previous approaches that used models of increasing complexity for
parameter initialisation (Bilgel et al., 2016), we initialise zlk using a
simpler clustering method, k-means clustering, of the vectors Vl. We also
tried other informed starting points for zlk based on splitting the histo-
gram of V into K parts, one for each cluster, as well as atlas based initi-
alisation. However, we found that the initialisation using k-means always
converged to the solution with highest likelihood. For initialisation of θ,
we set each sigmoid parameter (minimum, maximum, centre, slope)
based on the biomarker (i.e. vertex) values and the DPS range of the
subjects; we also initialise λ to 1. At each EM loop, to ensure the algo-
rithm doesn't get stuck in a local minimum, we also use 15 perturbed
starting points for each θk, 3 starting points for αi and βi and 20 for λ.We
take the best solution every time.
To ensure model identiﬁability, we need to account for extra degrees
of freedom in DIVE. First, the DPS scores have two extra degrees of
freedom (scale and shift), which we account for by setting informative
gamma and Gaussian priors on parameters αi and βi respectively
(αi~ Γ(16e4, 16e4), βi ~ N(0, 0.1)). These informative priors further aid170convergence and work well in practice as they result in realistic ranges
for αi and βi of around [0.3, 3] and [-15,15] respectively. Such infor-
mative priors on αi and βi and help deal with singularities in the objective
functions of αi and βi when the biomarker trajectories are ﬂat. Secondly,
as already explained in (Jedynak et al., 2012), the sigmoid parameters θk
are not identiﬁable, so we need to apply the following transformation on
line 5 of Alg. 1: if bk(u) < 0 then ak(u)¼ – ak(u); bk(u)¼ – bk(u); dk(u)¼ dk(u) – ak(u).
To make the DPS scores more interpretable, we normalise them so
that the DPS scores of controls have a mean of 0 and standard deviation of
1 (Alg. 1, line 20). This means that a DPS score above 1 will reﬂect the
presence of pathology. The DPS scores will also be comparable between
different cohorts if the same control population is used (e.g. DRC tAD vs
DRC PCA, see section 2.5). However, DPS scores are not comparable
between different datasets (ADNI vs DRC) or different modalities (MRI vs
PET).
As a Bayesian generative model, DIVE can automatically deal with
missing data by restricting the objective function (Alg 1 lines 4,9 and 12)
to only use available data.
2.3.2. Estimating the optimal number of clusters
The EM procedure needs to specify a-priori the number of clusters to
ﬁt on the data. We optimise the number of clusters K using Akaike In-
formation Criterion (AIC), which we found to better agree with ground
truth in simulations than other information criteria such as the Bayesian
Information Criteria (BIC). The number of parameters of the ﬁtted model
is 5Kþ2S þ 1, where S is the number of subjects. Note that zlk are not
included as parameters of the model because they are latent variables
that are marginalised (see Eq. (6)). We repeat the ﬁtting procedure for
each K from 2 to 100 clusters and select the K that minimises the AIC.
2.4. Simulation experiments
2.4.1. Motivation
Initial assessment of DIVE performance uses synthetic data, where we
know the ground truth. The aim is to explore how accurately we can
recover ground truth parameters as the problem becomes harder in three
different scenarios:
Scenario 1: as the number of clusters increases, evaluate how well
DIVE can estimate the correct number of clusters using AIC and BIC.
Scenario 2: as the trajectories become more similar, test how well we
can recover the assignment of vertices to clusters and the DIVE
parameters.
Scenario 3: same as Scenario 2, but for decreasing number of subjects.
2.4.2. Synthetic data generation
We ﬁrst designed a basic simulation, which the model should be able
to ﬁt well since the trajectories were designed to be well separated and
enough subject data was generated along the disease time course. The
data in the basic simulation was generated as follows:
1. Sample age ai1 and subject-speciﬁc parameters αi, βi for 300 subjects
with 4 timepoints (each timepoint 1 year apart), with ai1 ~ U(40,80),
αi ~ Γ(6.25, 6.25), βi ~ N(0, 10). Time since baseline has been ob-
tained for every visit j of subject i as follows: tij¼ aij – ai1
2. Generate three sigmoids with different (slope, centre) parameters:
[(-0.1, 15), (0.1, 2.5), (0.1, 20)] (Fig. 2A, red lines). Upper and
lower limits have been set to 1 and 0 respectively.
3. Randomly assign every vertex l 2 [1, …, L] where L¼ 1000, to a
cluster a[l] 2 [1,2,3]
4. Sample a set of L perturbed trajectories θl from each of the original
trajectories, one for each vertex (Fig. 2A, gray lines) using covariance
matrix Cθ¼ diag([0, 2bk/15, 11.6, 0]).
5. Sample subject data for every vertex l from its corresponding per-
turbed trajectory θl with noise standard deviation σl¼ 1.
From the basic simulation, we generated synthetic data for each of the
Fig. 2. (A–B) Results for the basic simulation, where trajectories are relatively well separated. (A) Reconstructed temporal trajectories (blue) plotted against the true
trajectories (red). The x-axis shows the disease progression score (DPS), while the y-axis shows the biomarker values of the vertices. (B) Estimated subject-speciﬁc DPS
scores compared to the true scores. (C–E) Simulation results for the three scenarios: (C) increasing number of clusters, (D) trajectories becoming similar and (E)
decreasing number of subjects. On the x-axes we show the variable that was changing within each scenario: true number of clusters, distance between trajectory
centres and the number of subjects. X-axis tick marks are equally spaced to improve visualisation, with increasing problem complexity from left to right. On the y-axis
we show the agreement measure א, representing the percentage of vertices that were assigned to the correct cluster.
R.V. Marinescu et al. NeuroImage 192 (2019) 166–177three scenarios by varying one parameter at a time and kept the other
parameters constant, having the same values as in the basic simulation.
We varied the following parameters:
Scenario 1: number of clusters - 2, 3, 5, 10, 15, 20, 30 and 40. The
cluster centres were spread evenly across a ﬁxed total DPS range where
data was available.
Scenario 2: distance δ between trajectory centres δ¼ c2 – c1¼ c3 – c2
(as proportion of total DPS range sampled) – 0.33, 0.30, 0.23, 0.17, 0.10,
0.07, 0.03 and 0.02.
Scenario 3: number of subjects - 300, 200, 100, 50, 35, 20, 10 and 5.
2.4.3. Model ﬁtting and evaluation
Since there was no spatial information in the data generation pro-
cedure, we used DIVE without the MRF extension. For Scenario 1, we
estimated using AIC and BIC the optimal number of clusters. For Sce-
narios 2 and 3, after ﬁtting the parameters of DIVE, we calculated the
agreement between the ﬁnal clustering probabilities p(Zl) and the true
clustering assignments a[l]. This agreement, which we will call the
clustering agreement, is deﬁned as א¼ maxτ (1/L)ΣLl¼1 p(Zl¼ τ(a[l])),
where τ is any permutation of cluster labels. We also computed the error in
the DPS estimation (sum of squared differences, SSD) and trajectory
estimation (SSD between predicted trajectory and true trajectory at DPS
points of every subject visit).2.5. Data acquisition and pre-processing
Data used in this work were obtained from the Alzheimer's Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu) and from
the Dementia Research Centre, UK. For ADNI, we downloaded all T1 MR171images that have undergone gradient warping, intensity correction, and
scaling for gradient drift. We included subjects that had at least 3 scans,
to ensure we get a robust estimate of the subject speciﬁc parameters. This
resulted in 138 healthy controls, 235 subjects with mild cognitive
impairment (MCI) and 81 subjects with Alzheimer's disease.
We also downloaded all AV45 PET images from ADNI that were fully
pre-processed, having the tag 'Co-reg, Avg, Std Img and Vox Siz, Uniform
Resolution'. This meant that the images were co-registered, averaged
across the 6 ﬁve-minute frames, standardised with respect to the orien-
tation and voxel size and smoothed to produce a uniform resolution of
8mm full-width/half-max (FWHM).
The DRC dataset consisted of T1 MRI scans from 26 healthy controls,
23 PCA and 20 typical AD subjects with at least 3 scans each. All PCA
patients fulﬁlled the (Tang-Wai et al., 2004) criteria and (Mendez et al.,
2002) criteria based on clinical review. The typical AD patients all met
the criteria for probable Alzheimer's disease (Dubois et al., 2007, 2010).
Given that the ADNI and DRC datasets contained subjects with
different modalities or diseases, we ran DIVE independently on the
following four cohorts (see Table 1 for demographics):
1) ADNI MRI: controls, MCI and tAD subjects from ADNI (cortical
thickness data)
2) DRC tAD: tAD subjects and controls from the DRC dataset (cortical
thickness data)
3) DRC PCA: PCA subjects and controls from the DRC dataset (cortical
thickness data)
4) ADNI PET: AV45 scans from ADNI containing subjects with following
diagnoses: healthy controls, subjective memory complaints, early
MCI, late MCI and Alzheimer's disease.
Table 1
Demographics of the three cohorts used in our analysis. ADNI MRI and the DRC
cohorts were used for the cortical thickness analysis, while ADNI PET was used
for the PET AV45 analysis. MCI – mild cognitive impairment, SMC - subjective










CTL 138 4.4 1.1 76.3 5.2 52%
MCI 235 4.6 1.3 74.8 7.4 39%
AD 81 3.5 0.6 75.8 7.7 56%
DRC tAD
CTL 26 5.0 1.7 66.3 5.6 46%
AD 20 5.5 1.6 71.2 7.1 50%
DRC PCA
CTL 26 5.0 1.7 66.3 5.6 46%
PCA 23 4.2 1.3 62.7 6.5 30%
ADNI PET
CTL 141 2.4 0.5 85.6 3.7 46%
SMC 27 2.0 0.0 86.1 4.0 59%
EMCI 149 2.4 0.5 85.6 3.6 38%
LMCI 104 2.4 0.6 86.0 3.6 55%
AD 12 2.0 0.0 87.3 3.8 25%
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2.5.1.1. MR images. On both datasets, in order to extract reliable cortical
thickness measures, we ran the Freesurfer longitudinal pipeline (Reuter
et al., 2012), which ﬁrst registers the MR scans to an unbiased
within-subject template space using inverse-consistent registration. The
longitudinally registered images were then registered to the average
Freesurfer template. No further smoothing was performed on these im-
ages (FWHM level of zero mm). From these template-registered volu-
metric images, cortical thickness measurements were computed at each
vertex (i.e. point) on an average 2D cortical surface manifold. For each
vertex we averaged the thickness levels from both hemispheres. Finally,
we standardised the data from each vertex with respect to the values of
that vertex in the control population. Each of the ﬁnal images had a
resolution of 163,842 vertices on the cortical surface.
2.5.1.2. PET AV45 images. We computed amyloid SUVR levels using the
PetSurfer pipeline (Greve et al., 2014, 2016), which is available with
Freesurfer version 6. The PetSurfer pipeline ﬁrst registers the PET image
with the corresponding MRI scan, then applies Partial Volume Correc-
tion, and ﬁnally resamples the voxelwise SUVR values onto the cortical
surface. While the ﬁnal images also had a resolution of 163,842 vertices,
the PET data we obtained from ADNI was inherently more smooth than
the MRI cortical thickness data (8mm FWHM).
2.5.2. The MRF neighbourhood graph
We estimated the MRF neighbourhood graph based on a Freesurfer
triangular mesh for the fsaverage template. Each vertex was a triangle on
the brain surface estimated with Freesurfer, and we connected the
vertices if the corresponding triangles had a shared edge. For the MRF
neighbourhood graph, we used a 3rd degree neighbourhood structure,
meaning that two vertices were considered neighbours if the shortest
path between them was not higher than 3.
3. Results
We ﬁrst present results on synthetic data (section 3.1), then on ADNI
and DRC datasets (section 3.2), followed by model evaluation (section
3.3) using cross-validation and correlation with cognitive markers.3.1. Results on synthetic data
In the basic simulation, we obtained a clustering agreement א of 0.97,172which suggests that almost all vertices were assigned to the correct
cluster. Fig. 2A shows the original trajectories and the recovered trajec-
tories using our model, plotted against the disease progression score on
the x-axis and the vertex value on the y-axis. In Fig. 2B we plotted the
recovered DPS of each subject along with the true DPS. The results for the
three scenarios are shown in Fig. 2C–E. In Fig. 2C, we show for Scenario 1
the estimated number of clusters against the true number of clusters
using both AIC and BIC criteria. In Fig. 2D and E we show the distribu-
tions for א in Scenarios 2 and 3 as the problem becomes harder in each
successive step.
The results show that, in a simple experiment where the trajectories
are well separated, DIVE can very accurately estimate which clusters
generated each vertex. Moreover, the recovered trajectories and DPS
scores are close to the true values. The results of Scenario 1 also suggest
that both AIC and BIC are effective at estimating the correct number of
known clusters, with AIC having slightly better performance than BIC for
larger numbers of clusters. On the other hand, the results of the stress test
scenarios 2 and 3 show that performance measure א drops when the
trajectories become very similar with each other or when the number of
subjects decreases. This happens because small differences in trajectories
are hard to detect in the presence of measurement noise, while a small
number of subjects doesn't provide enough data to accurately estimate
the parameters. Similar decreases in performance for scenarios 2 and 3
are observed also for other measures, such as the error in recovered
trajectories or DPS scores (Supplementary Fig. 1).
3.2. Results on ADNI and DRC datasets
3.2.1. Initial hypotheses
Using ADNI and DRC datasets, we aim to recover the spatial distri-
bution of cortical atrophy and amyloid pathology, as well as the rate and
timing of these pathological processes. In particular, we hypothesise that
these spatial patterns of pathology and their evolution will be:
1. Similar on two independent typical AD datasets: ADNI and DRC
2. Different on distinct diseases: tAD vs PCA
3. Different in distinct modalities: cortical thickness from MRI vs amy-
loid load from AV45 PET.
3.2.2. Results
The optimal number of clusters, as estimated with AIC, was three for
the ADNI MRI dataset, three for the DRC tAD dataset, ﬁve for the DRC
PCA dataset and eighteen for the ADNI PET dataset. Fig. 3A-left shows
the results from the ADNI MRI dataset, where in the left image we col-
oured the vertices on the cortical surface according to the cluster they
most likely belong to. We assigned a colour for each cluster (both the
brain ﬁgures on the left and the trajectory ﬁgures on the right) according
to the extent of pathology of its corresponding trajectory at a DPS score of
1. The cluster colours range from red (severe pathology) to blue (mod-
erate pathology). In Fig. 3A-right, we show the resulting cluster trajec-
tories with samples from the posterior distribution of each θk. Similar
results are shown for the other three datasets: the DRC tAD dataset
(Fig. 3B), DRC PCA dataset (Fig. 3C) and the ADNI PET dataset (Fig. 3D).
To better visualise the continuous progression of pathology, we show
movies of the pathology progression for all four datasets (Movie 1, online
version only).
Supplementary video related to this article can be found at https://d
oi.org/10.1016/j.neuroimage.2019.02.053.
We notice that in tAD subjects using the ADNI datasets (Fig. 3A), there
is more severe cortical thinning mainly in the inferior temporal lobe (red
cluster), with disperse atrophy also in parietal and frontal regions (green
cluster), with relative sparing of the inferior frontal and occipital lobes. In
tAD subjects from the DRC dataset, we see a relatively similar pattern,
however with more pronounced atrophy in the supramarginal cortex (red
cluster) compared to ADNI. The spatial distribution of cortical thinning
found with DIVE resembles results from previous longitudinal studies
Fig. 3. (left column) DIVE estimated clusters (left column) and corresponding
disease progression trajectories (right column) on four datasets: (A) ADNI MRI
(B) DRC tAD (C) DRC PCA and (D) ADNI PET. We coloured each cluster ac-
cording to the extent of pathology (cortical thickness or amyloid uptake)
at DPS¼ 1.
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to these approaches, our model gives insight into the timing and rate of
atrophy and is also able to stage subjects across the disease time course.
We also ﬁnd that the cluster trajectories in the DRC tAD dataset have
similar dynamics to the ADNI MRI dataset, although they show a clearer
separation between each other.
In the PCA subjects (Fig. 3C), we ﬁnd that atrophy is mainly focused
on the posterior part of the brain, with limited spread in the motor cortex,
anterior temporal and frontal areas. This posterior-focused pattern of
atrophy is different from the one found in the tAD datasets, and agrees
with previous ﬁndings in the literature (Crutch et al., 2012; Lehmann
et al., 2011). However, as opposed to the results from (Lehmann et al.,1732011), we notice that there are two clusters within the posterior region
with different pathology dynamics, with the superior parietal and
supramarginal areas affected more that the remaining posterior regions.
This might be attributable to DIVE's ability to model the disease onset and
progression speed for every individual and non-linear cortical thinning
dynamics. However, other differences in the datasets and pre-processing
pipelines might also inﬂuence the results.
In ADNI PET (Fig. 3D) we see that the regions with the highest am-
yloid uptake are more spatially continuous, comprising the precuneus
and anterior frontal areas. On the other hand, the anterior-superior
temporal gyrus shows the least uptake of amyloid. This result closely
matches the result by (Bilgel et al., 2016), which used a completely
different dataset and modelling technique. The “layers of clusters”
starting from the precuneus and frontal lobes, which range from severe to
less severe atrophy, suggest a continuum of variation in vertex trajec-
tories in the case of the PET dataset (Fig. 3D-right). These trajectories all
start with a low amyloid SUVR, between 0 and 0.25, but in late stages the
trajectories for some clusters such as cluster 0 can reach an SUVR of 1.5.
The reason for seeing this continuum might be because the PET images
have a much lower resolution than MR images and were smoothed by
ADNI during the pre-processing steps.
3.3. Model evaluation
3.3.1. Motivation
We further tested the robustness and validity of the model as follows:
1. Robustness in parameter estimation: test whether similar spatial clus-
tering is estimated for different subsets of the data
2. Clinical validity of DPS scores: test whether the subject disease pro-
gression scores, based purely on MRI or PET data, correlate with
cognitive tests such as Clinical Dementia Rating Scale - Sum of Boxes
(CDRSOB), Alzheimer's Disease Assessment Scale - Cognitive (ADAS-
COG), Mini-Mental State Examination (MMSE) and Rey Auditory and
Verbal Learning Test (RAVLT).
4. Comparison with other models: to evaluate the beneﬁt of estimating
ﬁne-grained patterns of pathology in DIVE, as well as latent time
shifting of subjects, we compared the performance of DIVE with two
standard approaches: (1) an ROI-based method, which groups vertices
based on an a-priori atlas like the approach of (Jedynak et al., 2012) –
this is a special case of DIVE where latent variables zlk are ﬁxed
instead of being marginalised – and (2) a no-staging model that doesn't
estimate subject time shifts and progression speeds (i.e. ﬁxes αi¼ 1,
βi¼ 0).
3.3.2. Evaluation procedure
For all scenarios, we ran 10-fold cross-validation (CV) on the ADNI
MRI dataset. At each fold we ﬁt the model using 3 clusters, since this was
the optimal number of clusters found previously on the entire dataset.
The trained model was then used to estimate the DPS of the test subjects.
For the performance comparison of DIVE with other models, we
compute two performancemetrics: (1) between-subject correlation of the
models' estimated DPS values with cognitive tests, which evaluates the
models' ability to map brain-behaviour relationships; here we estimated a
unique DPS for every subject and every visit, which we then matched
with the corresponding cognitive tests at that subject's visit and (2)
prediction root mean squared error (RMSE) between the predicted
vertex-wise values and actual measurements, averaged over all subjects
and all locations on the brain; to evaluate these predictions, for every
subject we use the ﬁrst n-1 scans for training and the last scan for testing
the prediction.
3.3.3. Evaluation results
Fig. 4 shows the brain clusters and corresponding trajectories, esti-
mated for all the cross-validation folds after ﬁtting the model on the
training data. The clusters have been coloured using a similar colour
Fig. 4. (top) Clusters estimated from 10-fold cross-validation training sets on the ADNI MRI dataset. (bottom) Estimated trajectories for each fold.
R.V. Marinescu et al. NeuroImage 192 (2019) 166–177scheme as in Fig. 3. In Fig. 5 we show scatter plots of the DPS scores with
clinical measures such as CDRSOB, ADAS-COG, MMSE and RAVLT.
The results in Fig. 4 demonstrate that DIVE is robust in cross-
validation, as the estimated clusters and trajectory parameters are all
similar across folds. The average Dice score overlap across the 10-folds
range were 0.77, 0.76 and 0.90 for clusters 0, 1 and 2 respectively. The
DIVE-derived DPS scores, which were estimated purely based on MRI
data, are also clinically relevant as they correlate with cognitive tests
(Figs. 5, 0.32 < ρ 0.38, p 1e-38). These results are also comparable with
correlations between whole brain cortical thickness measures and
cognitive tests: CDRSOB (ρ¼0.40, p< 1e-76), ADAS-Cog (ρ¼0.40,
p< 1e-76), MMSE (ρ¼ 0.40, p< 1e-76), RAVLT (ρ¼ 0.34, p< 1e-56).Fig. 5. Scatter plots of the DPS scores estimated from the ADNI MRI dataset, plotted
cognitive test we also report the correlation coefﬁcient and p-value. The disease progr
these cognitive measures, suggesting that the DPS scores are clinically meaningful.
174Moreover, all the subject-speciﬁc parameters (time shifts, progression
speeds) and the DPS scores show signiﬁcant differences (p< 0.013) be-
tween the APOE-positive and -negative groups (Supplementary Fig. 2),
suggesting they correlate also with genetic features.
When evaluating the DIVE's performance in terms of subject staging
and biomarker prediction (Table 2), it performs better than the no-staging
model due to its ability to estimate subject-speciﬁc parameters, and has
similar performance to the ROI-basedmodel. However, as opposed to the
more parsimonious ROI-based model, DIVE offers qualitative insight into
the ﬁne-grained spatial patterns of pathology and their temporal
progression.against four cognitive tests: CDRSOB, ADAS-COG, MMSE and RAVLT. For each
ession scores, computed only based on MRI cortical thickness data, correlate with
Table 2
Performance evaluation of DIVE and two other models on the ADNI MRI dataset using 10-fold cross-validation. In the middle four columns, we show between-subject
correlations between the DPS scores and several cognitive tests: CDRSOB, ADAS-Cog 13, MMSE and RAVLT. The last column shows the prediction error (RMSE) of
cortical thickness values for follow-up scans. (*) Statistically signiﬁcant differences between the model and DIVE, Bonferroni corrected for multiple comparisons.
Model CDRSOB (ρ) ADAS13 (ρ) MMSE (ρ) RAVLT (ρ) Prediction (RMSE)
DIVE 0.370.09 0.370.10 0.360.11 0.320.12 1.0210.008
ROI-based model 0.360.10 0.350.11 0.340.13 0.300.13 1.0190.010
No-staging model *0.090.06 *0.030.09 *0.050.06 *0.020.06 *1.0620.024
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4.1. Summary and key ﬁndings
We presented DIVE, a spatiotemporal model of disease progression
that clusters vertex- or voxel-wise measures of pathology in the brain
based on similar temporal dynamics. The model highlights, for the ﬁrst
time, groups of cortical vertices that exhibit a similar temporal trajectory
over the population. The model also estimates the temporal shift and
progression speed for every subject. We applied the model on cortical
thickness vertex-wise data from three MRI datasets (ADNI, DRC tAD and
DRC PCA), as well as an amyloid PET dataset (ADNI). Our model found
qualitatively similar patterns of cortical thinning in tAD subjects using
the two independent datasets (ADNI and DRC). Moreover, it also found
different patterns of pathology dynamics on two distinct diseases (tAD
and PCA) and on different types of data (PET and MRI-derived cortical
thickness). Finally, DIVE also provides a new way to parcellate the brain
that is speciﬁc to the temporal trajectory of a particular disease, and
enables staging of individuals at risk of disease, which may potentially
help stratiﬁcation in clinical trials.
4.2. Effect of training data on DIVE results
The characteristics of the subjects used for training can affect the
DIVE parameters. For example, while we could not include MCI subjects
in the DRC dataset due to unavailability, such subjects in middle stages
should be included to accurately estimate the DIVE parameters. More-
over, in cortical thinning analyses we standardised the data with respect
to controls, which might have already shown cortical thinning due to
early pathology. This can be mitigated through enrichment of the control
population to amyloid-negative individuals. To reliably estimate the
subject-speciﬁc parameters, multiple follow-up scans are required. We
mitigated this by using only subjects with at least three scans, and further
placing informative priors on these parameters. However, DIVE can still
be used on cross-sectional datasets due to the informative priors placed
on subject-speciﬁc para meters; however, we expect higher parameter
uncertainty in these regimes.
4.3. Interpretation of spatial patterns and trajectories
The DIVE-estimated spatial patterns are patchier in MRI compared to
PET scans, which had lower resolution and were smoothed a-priori.
However, this does not suggest the MRI should be smoothed a-priori, as
the spatial correlation mechanismwithin DIVE enables it to remove high-
frequency patterns that are not meaningful automatically. More pre-
cisely, as the “hole-ﬁlling” parameter λ is automatically optimised based
on the input data, this enables DIVE to identify the optimal smoothness
level speciﬁc to the types and size of input data analysed. Moreover, such
a-priori smoothing could potentially loose dispersed patterns of pathol-
ogy that arise due to underlying disruption of brain networks.
While the DIVE-estimated trajectories in the DRC tAD dataset are
similar to the ones in ADNI MRI, they show less variance and higher
separation between clusters. We attribute this to both the inclusion of
MCI patients in ADNI and to the smaller sample size of the DRC dataset.
In particular, MCI subjects are highly heterogenous and some have non-
AD underlying pathologies, so including them can increase the trajectory175variance. Furthermore, the small sample size can also result in lower
variance due to less datapoints available to estimate the trajectories.
As less assumptions are made in DIVE about disease progression
compared to previous modelling approaches, there could be differences
in the resulting spatial patterns of pathology and its evolution. As
compared to voxel-basedmorphometry studies where spatial patterns are
highlighted only if signiﬁcant differences from controls exist, DIVE can
highlight early patterns of mild pathology that are also present in con-
trols. There are some implications to this; for example, DIVE could be
used to study the normal ageing process. Moreover, as clusters of vertices
with similar evolution are optimally derived from the data, this can result
in more sensitive biomarkers that can be used for earlier prediction of
dementias.
4.4. Model evaluation
In some cortical thickness prediction tasks (Table 2), DIVE showed
some improvements over standard approaches, although the margin of
improvement is small. This is because the vertex-wise prediction problem
is itself very challenging due to high spatial noise and the lack of a-priori
smoothing. Moreover, DIVE was not optimised speciﬁcally for this pre-
diction task – our key aim was to improve interpretability of disease
progression modelling. Similarly, the correlations between DPS scores
and cognitive tests are comparable, yet don't show signiﬁcant improve-
ments over direct correlations of whole brain cortical thickness with
cognitive tests. This can be attributed to cognitive tests becoming
affected later than MRI atrophy, along with other characteristics of the
analysed data (inherent noise and limited number of scans).
4.5. Limitations and future work
DIVE has some limitations that can be addressed. First, we assumed
that cluster trajectories follow sigmoidal shapes, which is not the case for
many types of biomarkers in ADNI which do not plateau in later stages.
The assumption of sigmoidal trajectories can be avoided using non-
parametric curves such as Gaussian Processes (Lorenzi et al., 2017),
which would be straightforward to incorporate into the DIVE framework.
DIVE also assumes a single trajectory within one cluster to avoid
complexity, although in reality there is within-cluster trajectory vari-
ability. However, simulations have shown that the single-trajectory
simpliﬁcation is sensible as DIVE can still accurately estimate the mean
trajectory. Moreover, DIVE inherently minimises the within-cluster
variance as it minimises the sum of squared differences under the
Gaussian noise model. However, non-Gaussian variability can exist, e.g.
due to registration working better in some regions, so future work can
take registration uncertainty into account.
Another limitation of the model is that it assumes all subjects follow
the same disease progression pattern, which might not be the case in
heterogeneous datasets such as ADNI or DRC. This can be a concern, as
there might be a pattern of pathology that occurs in a small set of sub-
jects. However, DIVE can be extended to account for heterogeneity in the
datasets by modelling different progression dynamics for distinct sub-
groups, using random effects like in (Donohue et al., 2014) or unsuper-
vised learning methods like the SuStaIn model (Young et al., 2018).
While SuStaIn, just like DIVE, estimates clusters and trajectories within
the dataset, the clusters in SuStaIn are made of subjects with similar
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similar progression. Future work could combine clustering along both
subjects and vertices simultaneously to estimate disease subtypes with
distinct spatiotemporal dynamics at the vertexwise level.
Our work also has some limitations regarding parameter estimation.
Firstly, the EM framework can sometimes converge to a local minimum.
While we accounted for this using informed starting points and setting
informative priors on the parameters, future work can explore other
approaches such as stochastic EM or reversible-jump Markov Chain
Monte Carlo (MCMC); moreover, reversible-jump MCMC would allow us
to also estimate the optimal number of clusters simultaneously with the
other parameters. Secondly, to get a reliable estimate of the subject-
speciﬁc parameters, we ran DIVE only on balanced datasets, where
subjects had at least three scans. However, DIVE can also be applied to
less balanced datasets, by setting stronger priors on these parameters or
even ﬁxing the progression speed for every subject to 1.
There are several potential future applications of DIVE. One of the
advantages of DIVE is that it can be used to study the link between
disconnected patterns of brain pathology and connectomes extracted
from diffusion tractography or functional MRI (fMRI). Such an analysis
would enable further understanding of the exact underlying mechanisms
by which the brain is affected by the disease. Our model, which can es-
timate ﬁne-grained spatial patterns of pathology, is more suitable than
standard ROI-based methods for studying the link between pathology
and these structural or functional connectomes, because white matter or
functional connections have a ﬁne-grained and spatially-varying distri-
bution of endpoints on the cortex.
Apart from studying the link with brain connectomes, there are other
potential applications for DIVE. While we only applied it to vertexwise
data, the model can also be applied to study voxelwise data. Moreover,
DIVE can be applied to other modalities or types of data, including FDG
PET, tau PET, DTI or Jacobian compression maps from MRI. Moreover,
the model can also be extended to cluster points on the brain surface
according to a more complex disease signature, that can be made of two
or more biomarkers. For example, using our cortical thickness and am-
yloid PET datasets from ADNI, we could have clustered points on the
brain based on both modalities simultaneously. Such complex disease
signatures can offer important insights into the relationships between
different modalities and underlying disease mechanisms.
5. Conclusion
DIVE is a spatiotemporal model that can be used for accurately pre-
dicting and staging patients across the progression timeline of neurode-
generative diseases. The spatial patterns of pathology can also be used to
test mechanistic hypotheses which consider AD as a network vulnera-
bility disorder. All these avenues can help towards disease understand-
ing, patient prognosis, as well as clinical-trials for assessing efﬁcacy of a
putative treatment for slowing down cognitive decline.
DIVE availability
DIVE source code, written in Python 3, is available at https://github
.com/mrazvan22/dive and can be easily applied on any registered vox-
elwise or vertexwise images. ADNI data can be downloaded from the
Laboratory of NeuroImaging at the University of Southern California.
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